IPOs get back into gear with filings from LianBio and Xilio, and Cormorant's SPAC has a deal
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
As the fourth quarter gets underway, the biotech IPO market is revving its engines back up.
Two more companies filed to make their Nasdaq debuts Friday, Xilio Therapeutics and LianBio, each penciling in the standard $100 million estimate. There was also a SPAC merger that landed early Monday morning, as a blank check company from Cormorant Asset Management reverse merged with Swiss biotech MoonLake Immunotherapeutics in a $230 million deal.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.